Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Buerger's Disease

Recruiting now · Phase 4

Conditions studied: Critical Limb Ischemia, Buerger's Disease

In brief

The goal of this observational, practice-based feasibility study is to observe the efficacy and safety of intramuscular administration of Stempeucel® in Malaysian patients with critical limb ischemia (CLI) due to Buerger's disease. The main questions it aims to answer are: * Can intramuscular administration of Stempeucel® reduce symptoms of CLI due to Buerger's disease while improving the healing rate and functional outcomes? * Does intramuscular administration of Stempeucel® causes any serious adverse events in CLI due to Buerger's disease patients? Study patients will be assessed by the PI before administering the Stempeucel® for any other organ with inflammation. The study patients will also be followed up to the duration of 1 year after study treatment administration for safety and efficacy assessment.

Key facts

Study ID

NCT05854615

Run by

Cell Biopeutics Resources Sdn Bhd

People needed

3

Starts

2024-01-01

Expected to finish

2027-12-01

Last updated by the study team

2025-09-09

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males or females (willing to use accepted methods of contraception during the course of the study) in the age group of 18-65 years.
• Buerger's disease as diagnosed by Shionoya criteria
• Patients should have at least one ulcer (target ulcer): area between 0.5 to 10 cm2 (both inclusive)
• Ankle Brachial Pressure Index (ABPI) ≤ 0.6. If ABPI is ≥ 1.1 then Toe Brachial Index (TBI) will be performed and TBI should be ≤ 0.5
• Patients who are able to understand the requirements of the study, and willing to provide voluntary written informed consent, abide by the study requirements, and agree to return for required follow-up visits

You may not qualify if…

• Patients diagnosed with atherosclerotic peripheral arterial disease
• Patients eligible for surgical or percutaneous revascularization
• Patients with a history of participating in another stem cell trial or therapy within 3 months
• Patients who are unsuitable to participate the clinical trial as determined by investigators

Where it is running

• Hospital Canselor Tunku Mukhriz — Kuala Lumpur, Malaysia (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.